<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108301</url>
  </required_header>
  <id_info>
    <org_study_id>EK477/2011</org_study_id>
    <nct_id>NCT02108301</nct_id>
  </id_info>
  <brief_title>Hepatitis C in Renal Transplant Recipients</brief_title>
  <official_title>Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Alice Schmidt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The aim of the present trial is to evaluate whether the conversion of immunosuppression from
      tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters
      of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal
      transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in Hepatitis C-virus load at 12 weeks</measure>
    <time_frame>one day before and 4, 8 and 12 weeks after the conversion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in oral glucose insulin sensitivity (OGIS) index at 12 weeks</measure>
    <time_frame>one day before and 12 weeks after the conversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum hepcidin levels at 12 weeks</measure>
    <time_frame>one day before and 12 weeks after the conversion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>serum creatinine levels</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum glutamic-pyruvic transaminase concentrations</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Hepatitis C-virus Infection</condition>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>tacrolimus-cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus-cyclosporine A</intervention_name>
    <description>conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients</description>
    <arm_group_label>tacrolimus-cyclosporine A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  prior renal transplantation

          -  current tacrolimus-based immunosuppressive regimen

          -  hepatitis C-infection

          -  age 18-70 years

        Exclusion Criteria:

          -  current hemodialysis or peritoneal dialysis

          -  pregnancy or breastfeeding

          -  known contraindication for cyclosporine A-treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Alice Schmidt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis C-virus infection</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>glucose tolerance</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

